Latest Boardroom Shifts News

Vulcan Steel has appointed Gavin Street as its new CEO and managing director, while reshuffling key board roles to maintain a majority of independent directors.

Battery Age Minerals announces the upcoming departure of CEO Nigel Broomham, with a formal search underway for his successor as the company continues its growth trajectory.

Blackstone Minerals announces the resignation of Managing Director Scott Williamson, appointing Geoff Gilmour as Executive Chairman during the search for a new CEO. The board also welcomes geologist Greg Cunnold to strengthen technical expertise amid this transition.

Dome Gold Mines reports a substantial 19.9 million tonne construction sand resource at its Sigatoka project, alongside a key board appointment and licence renewal that advance its mining ambitions.

Elanor Investors Group has agreed to step down as manager of the Elanor Commercial Property Fund, accepting $8.5 million in compensation as Lederer Group moves to assume control. The transition promises fee savings and closer alignment with investors.

Celsius Resources has postponed the final Feasibility Study for its Maalinao-Caigutan-Biyog Copper-Gold Project to January 2026, while engaging a top financial advisory firm to secure project financing amid strong international interest.

Nutritional Growth Solutions announces the departure of CEO Stephen J. Turner, appointing Non-Executive Director Andrew Grover as interim CEO to steer the company through its next phase.

Elanor Commercial Property Fund has reaffirmed its FY26 distribution guidance of 6.5 cents per security, buoyed by strong leasing activity and a modest uplift in portfolio valuations. However, potential management changes could cloud future payouts.

Antony Sage, founding director of Cyclone Metals, has lodged an application with the Takeovers Panel alleging coordinated shareholder actions to alter the board without proper disclosure. The dispute intensifies as Cyclone schedules a new meeting to consider further director removals.

Chimeric Therapeutics has raised $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 trial through Phase 1, while initiating a strategic reset to sharpen focus and reduce costs.

Regis Healthcare announces the resignation of CEO Dr Linda Mellors after six years, with a transition period underway as the board searches for her successor.

Cann Group Limited has launched a comprehensive suite of option offers aimed at raising incremental capital, subject to shareholder approval at a December 23 meeting. The prospectus outlines potential dilution and financial impacts as the company seeks to strengthen its balance sheet.